Clinical Research Directory

Inclusion Criteria: 1. Age 6 to 18 years old. 2. Injury less than or equal to 4 days old 3. Non-fractured MSK soft-tissue injury (ankle or knee, confirmed clinically and/or radiographically) 4. Pain score of more than or equal to 3 on the verbal numerical rating scale, with movement in the past 2 hours or before analgesia Exclusion Criteria: 1. Previous enrolment in the trial 2. Barriers to topical treatment application, including skin conditions (e.g. eczema, infection, open wounds) or overlying material (e.g., rigid cast) which would make applying topical treatment impossible. 3. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could, in the opinion of the Qualified Medical Investigator or treating physician, would make the participant unsuitable for this study 4. Any contraindication to NSAID use including but not limited to a history of GI bleeding, gastric ulcer, inflammatory bowel disease, prior cerebrovascular bleeding, bleeding diathesis, interstitial kidney disease 5. Taking NSAIDs daily for other indications (e.g, chronic pain or arthritis) 6. Known hypersensitivity to ibuprofen, diclofenac or other NSAIDs. 7. Any known allergy or intolerance to any components (e.g., aloe vera) included in the oral or topical preparations of the investigational products 8. Current use of prohibited medications known to impair renal function when combined with NSAIDs or cause potential additive risks of gastrointestinal toxicity and renal impairment 9. Absence of a parent/guardian for children who are not mature minors. 10. Caregiver and/or child cognitive impairment precluding the ability to complete study procedures 11. Inability to obtain consent, and to complete follow-up surveys due to language barrier 12. Known or suspected late pregnancy (gestational age ≥20 weeks) at the time of enrolment or breastfeeding females, due to the risk of premature closure of the ductus arteriosus associated with NSAID use 13. Current enrollment in another pain-related clinical trial or in a study that, in the opinion of the Qualified Medical Investigator, may interfere with enrollment, involve investigational products that interact with study medications, or compromise follow-up and outcome assessment